Promising Phase 3 Data Could Propel Candel Therapeutics
AI Prediction of Candel Therapeutics, Inc. Common Stock (CADL)
Candel Therapeutics is poised for potential growth with upcoming clinical and regulatory catalysts that could significantly influence its stock price.
Candel Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing viral immunotherapies for cancer treatment. Its lead assets, aglatimagene besadenovec and linoserpaturev, target various cancers including prostate cancer and NSCLC. Key upcoming catalysts include the presentation of Phase 3 prostate cancer data and initiation of a Phase 3 trial for NSCLC. These events, coupled with a strengthened balance sheet and recent financial maneuvers to secure funding into Q1 2028, position the company in a potentially advantageous market position. Successful outcomes in these trials could lead to significant price movement due to the high unmet medical needs and substantial market sizes of the targeted indications.
CADL Report Information
Prediction Date2026-03-18
Close @ Prediction$5.17
Mkt Cap379m
IPO Date2021-07-27
AI-derived Information
Recent News for CADL
- Mar 17, 2:53 pm — Nasdaq rises with IBM, Goldman Sachs leading, as Iran strikes continue (Proactive)
- Mar 17, 10:35 am — Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 (Proactive)
- Mar 17, 8:05 am — Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors (GlobeNewswire)
- Mar 12, 9:33 am — Candel Therapeutics strengthens balance sheet as lead cancer therapy advances (Proactive)
- Mar 12, 8:05 am — Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
- Mar 9, 8:05 am — Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting (GlobeNewswire)
- Mar 2, 4:05 pm — Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Feb 24, 8:05 am — Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston (GlobeNewswire)
- Feb 20, 8:40 am — Candel Therapeutics prices $100M public offering (Proactive)
- Feb 20, 5:55 am — Why Is Candel Therapeutics Stock Falling Friday? (Benzinga)
- Feb 20, 4:57 am — Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers-Grail, Candel Therapeutics, Copart In Focus (Benzinga)
- Feb 19, 9:40 pm — Candel Therapeutics Announces Pricing of Public Offering (GlobeNewswire)
NDAPR (News-Driven AI Prediction Revision) events for CADL
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest